abediterol
Small moleculeexperimental
Abediterol is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed. — Wikipedia
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01425814)
Timeline
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=c1ccc2c([C@@H](O)CNCCCCCCOCC(F)(F)c3ccccc3)ccc(O)c2[nH]1- Mol. weight
- 460.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAbediterol ↗
- ChEMBLCHEMBL3039530 ↗
Also known as
- 5-(2-((6-(2,2-difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one
- abediterol
- abediterol
- abediterol
- abediterol
- abediterol
- las100977
- las100977
- las-100977
- las-100977
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04199598 | Phase 1 | Jan 10, 2020 | AstraZeneca, Parexel |
| NCT03273127 | Phase 1 | Sep 21, 2017 | AstraZeneca, Parexel |
| NCT02967159 | Phase 1 | Nov 24, 2016 | AstraZeneca, Parexel |
| NCT02777827 | Phase 1 | Jun 1, 2016 | AstraZeneca, Biebricher Allee, Wiesbaden, Germany |
| NCT01425801 | Phase 2 | Aug 1, 2011 | AstraZeneca |
| NCT01425814 | Phase 2 | Aug 1, 2011 | AstraZeneca |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2011 |
| Parexel | For profit | 3 | 0 | 1 | 2016 |
| Biebricher Allee, Wiesbaden, Germany | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1